Can you take Ranolazine with Tyrvaya?

The varenicline in Tyrvaya has a moderate potential interaction with Acute Alcohol Intoxication.

Varenicline can enhance the response to alcohol and patients may experience increased intoxicating effects. In patients who may use alcohol excessively, it should be kept in mind that the potentiation may increase the danger associated with the use of alcohol. Advise patients to reduce the amount of alcohol they consume and to use caution driving or operating machinery or engaging in other potentially hazardous activities while taking varenicline until they know how this agent may affect them.

The varenicline in Tyrvaya has a moderate potential interaction with Cardiovascular Conditions and Disorders.

There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline. Caution is recommended when prescribing this agent. Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.

The varenicline in Tyrvaya has a major potential interaction with Depressive Psychosis.

Serious neuropsychiatric events including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide have been reported in patients taking varenicline. Caution is recommended and patients should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide.

The varenicline in Tyrvaya has a moderate potential interaction with Heart Attack.

There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline. Caution is recommended when prescribing this agent. Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.

The varenicline in Tyrvaya has a moderate potential interaction with History - Cerebrovascular Disease.

There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline. Caution is recommended when prescribing this agent. Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.

The varenicline in Tyrvaya has a moderate potential interaction with History - Myocardial Infarction.

There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline. Caution is recommended when prescribing this agent. Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.

Ranolazine has a major potential interaction with Liver Disease.

Plasma concentrations of ranolazine increased by 30% in patients with mild (Child-Pugh Class A), and by 60% in patients with moderate (Child-Pugh B) hepatic impairment. The use of ranolazine is contraindicated in patients with clinically significant hepatic impairment.

Ranolazine has a moderate potential interaction with Long QT Syndrome.

Ranolazine prolongs the QT interval in a dose-related manner. Caution should be exercised if used in patients with long QT interval, or using other QT- prolonging drugs.

The varenicline in Tyrvaya has a major potential interaction with Psychiatric Disorders.

Serious neuropsychiatric events including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide have been reported in patients taking varenicline. Caution is recommended and patients should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide.

Ranolazine has a moderate potential interaction with Renal Dysfunction.

In patients with varying degrees of renal impairment, ranolazine plasma levels increased up to 50%, Caution is advised when used in patients with renal impairment. The pharmacokinetics of ranolazine has not been assessed in patients on dialysis.

The varenicline in Tyrvaya has a moderate potential interaction with Renal Dysfunction.

Varenicline is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Dose reduction is not required in patients with mild to moderate renal impairment. Dosage adjustment is needed in patients with severe renal impairment, and those with end-stage renal disease undergoing hemodialysis. Varenicline has been shown to be dialyzed in patients with end-stage renal disease. Monitoring of renal function is recommended.

The varenicline in Tyrvaya has a moderate potential interaction with Seizures.

Seizures have been reported with varenicline therapy. Therapy with this drug should be administered with caution and monitoring is recommended in patients with a history of seizures or other factors that can lower the seizure threshold.